Champions Oncology Inc CSBR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CSBR is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $5.03
- Day Range
- $5.06–5.14
- 52-Week Range
- $4.17–7.32
- Bid/Ask
- $5.03 / $5.31
- Market Cap
- $68.78 Mil
- Volume/Avg
- 1,477 / 3,908
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.39
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 0.11%
Company Profile
Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 230
Comparables
Valuation
|
Metric
|
CSBR
|
ADPT
|
BEAM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 1.23 | 1.80 |
Price/Sales | 1.39 | 2.21 | 4.41 |
Price/Cash Flow | — | — | — |
Price/Earnings
CSBR
ADPT
BEAM
Financial Strength
|
Metric
|
CSBR
|
ADPT
|
BEAM
|
|---|---|---|---|
Quick Ratio | 0.56 | 4.37 | 5.79 |
Current Ratio | 0.60 | 4.66 | 5.89 |
Interest Coverage | — | −16.45 | — |
Quick Ratio
CSBR
ADPT
BEAM
Profitability
|
Metric
|
CSBR
|
ADPT
|
BEAM
|
|---|---|---|---|
Return on Assets (Normalized) | −26.33% | −18.06% | −3.95% |
Return on Equity (Normalized) | −351.72% | −35.04% | −6.58% |
Return on Invested Capital (Normalized) | −76.87% | −28.06% | −9.14% |
Return on Assets
CSBR
ADPT
BEAM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jqtqtfbpv | Mjfbb | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zfqlbkvt | Wvsdp | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fqkfscrrj | Ndjdjv | $97.8 Bil | |
MRNA
| Moderna Inc | Rlbkpydc | Jzwqk | $38.8 Bil | |
ARGX
| argenx SE ADR | Khyryjnz | Byss | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Hqwpgkwy | Rmbjp | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Nlnkjch | Qnzdb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zzfpyczn | Zxpnssq | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pvvpydyc | Wckxgf | $12.5 Bil | |
INCY
| Incyte Corp | Vxgnsfxn | Ktvxcn | $11.5 Bil |